Description

As the FDA increasingly adopts AI-driven risk analysis and advanced compliance monitoring tools to identify high-risk facilities, pharmaceutical and biotech companies must transition from periodic inspection preparation to continuous inspection readiness.

This intensive one-day, in-person seminar provides practical strategies to help organizations prepare for evolving FDA inspection models, data-driven enforcement trends, AI-assisted risk targeting, and increasing regulatory expectations surrounding GMP compliance, data integrity, CAPA effectiveness, and quality culture.

Participants will learn how to strengthen inspection readiness programs, reduce compliance vulnerabilities, and build sustainable systems that support perpetual regulatory readiness — and will leave with a facility-specific action plan developed during a hands-on mock inspection workshop.

Agenda:-

9:00 – 9:15 AM - Welcome & Course Overview

Morning — FDA AI-Driven Inspection Risk & Compliance Expectations

9:15 – 10:00 AM

Session 1: The Future of FDA Inspections in 2026

• FDA’s evolving risk-based inspection strategy
• How AI and data analytics are influencing inspection prioritization
• Understanding high-risk facility indicators
• FDA enforcement trends and warning letter analysis
• Impact of repeat observations and compliance history

10:00 – 11:15 AM

Session 2: AI-Driven Risk Signals & Data Integrity Red Flags

• Data integrity risks attracting regulatory attention
• Electronic records and metadata review trends
• CAPA effectiveness and recurring deviation analysis
• Quality metrics and complaint trending
• Supplier and vendor oversight risks

11:15 – 11:30 AM - Morning Break

11:30 – 12:00 PM - Topics continued after lunch

Session 3: Building a State of Perpetual Inspection Readiness

• Moving beyond inspection preparation
• Creating sustainable inspection-ready systems
• Documentation and record readiness strategies
• Internal audit best practices
• Inspection readiness governance models

Noon – 12:45 PM - Networking Lunch

Afternoon — Practical Strategies for Inspection Success & Regulatory Defense

12:45 – 1:15 PM 

Session 3: Building a State of Perpetual Inspection Readiness Continued

1:15 PM – 2:00 PM

Session 4: Human Error, Quality Culture & Operational Risk

• Human error as a leading inspection risk factor
• Building a proactive GMP quality culture
• Training effectiveness and competency management
• Supervisory oversight and accountability
• Reducing repeat failures and deviations

2:00 – 3:00 PM

2:30 – 2:45 PM - Afternoon Break 

Session 5: Managing FDA Inspections & Investigator Interactions

• Preparing teams for unannounced inspections
• FDA investigator interview management
• Managing document requests and inspection flow
• Inspection communication best practices
• Remote and hybrid inspection expectations

3:00 – 3:45 PM

Session 6: CAPA, Investigations & Compliance Remediation

• FDA expectations for investigations and CAPAs
• Root cause analysis best practices
• Avoiding weak or ineffective corrective actions
• Building sustainable remediation plans
• Inspection response documentation

3:45 – 4:15 PM

Session 7: Regulatory Changes & Emerging Topics

• Recent FDA guidance and GMP regulatory updates impacting inspections
• Expanded unannounced foreign inspections and FDA onshoring initiatives
• AI in GMP operations: EU GMP Annex 22 and FDA AI guidance expectations
• Computerized systems and data governance: EU GMP Annex 11 and Chapter 4 revisions
• Global harmonization and ICH updates (e.g., ICH Q9(R1) quality risk management)

4:15 – 5:00 PM

Session 8: Mock Inspection Workshop & Action Planning

• Simulated FDA inspection scenarios
• Common inspection mistakes and red flags
• Building facility-specific readiness plans
• Developing continuous compliance improvement programs
• Implementation roadmap

Learning Objectives:-

• Understand how FDA AI-driven targeting may impact inspections
• Improve continuous inspection readiness strategies
• Reduce compliance risks and repeat observations
• Strengthen CAPA and investigation effectiveness
• Improve data integrity and documentation practices
• Build a stronger GMP quality culture
• Prepare teams for modern FDA inspection expectations

Areas Covered:-

• Free FDA Inspection Readiness Checklist 2026 — a practical tool to take back to your site
• Real Inspection Examples & Case Studies — lessons drawn from actual FDA findings
• Mock FDA Inspection Exercises — practice investigator interactions in a live setting
• Interactive Q&A — direct access to the instructor throughout the day
• Continuing Education Certificate — 8 hours of CE credit

Who Should Attend:-

• Quality Assurance Professionals
• GMP Compliance Teams
• Manufacturing & Operations Leaders
• Validation & CSV Professionals
• Regulatory Affairs Teams.